PT 606 - Ibogaine and the Future of Healing: Trevor Millar & Jonathan Dickinson of Ambio Life Sciences

n this episode of Psychedelics Today, kicking of Psychedelic Science 2025 week in Denver, we sit down with Jonathan Dicksinson, Chief Executive Officer, and Trevor Millar, Chief Operations Officer of Ambio Life Sciences – one of the world’s leading ibogaine clinics – to explore the potential of ibogaine for addiction, neuroregeneration, and how ethics, honoring experience, and sustainability will be key to delivering ibogaine at scale. 

Trevor shares his early work supporting marginalized populations in Vancouver’s Downtown Eastside, which led to the founding of Liberty Root, one of Canada’s first ibogaine clinics. Jonathan reflects on his apprenticeship in Mexican clinics, years of international advocacy with the Global Ibogaine Therapy Alliance, and drafting the first set of clinical guidelines for ibogaine detoxification. Together with paramedic and ibogaine safety protocols expert Jose Inzunza, they co-founded Ambio in Tijuana in 2021.

They discuss:

• The unique safety standards Ambio has pioneered – including industry-wide clinical protocols and magnesium therapy to mitigate cardiac risk.
  
  

• Their scale: over 3,000 patients treated, with 100+ clients per month across five dedicated houses in Baja California.
  
  

• Ambio’s groundbreaking neuroregenerative program for Parkinson’s, MS, and traumatic brain injury – which has already drawn patients like Brett Favre and Clay Walker.
  
  

• How ibogaine appears to drive profound physiological change – including evidence of TBI reversal as shown in Stanford’s 2024 study on Special Forces veterans.
  
  

• Why ibogaine isn’t just a molecule – it opens a long-lasting “critical period” of neuroplasticity that must be supported with preparation, integration, and holistic care.
  
  

• The deeper story of sourcing: through his company Terragnosis, Jonathan is the only person with a legal export license for Tabernanthe iboga from Gabon, and Ambio is setting a precedent for reciprocal and ethical global supply chains.
  
  

• Their cautionary perspective on Texas’ $50M push toward ibogaine clinical trials – and why the traditional “one drug, one indication” model misses the complexity and promise of psychedelic healing.

They also make a compelling case that Ambio is already modeling what the future of psychedelic care should look like – not a single drug in a sterile clinical setting, but a comprehensive, integrated protocol combining preparation, medical oversight, and deep integration. “Start with the end in mind,” Trevor urges – Ambio isn’t just part of the movement; it’s the blueprint for how ibogaine could be delivered worldwide.

Links:

• Ambio Website: https://ambio.life/

• Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis (Frontiers in Immunology, Feb 2025)

• Magnesium–ibogaine therapy in veterans with traumatic brain injuries (Nature Medicine, Jan 2024)